Vanguard Investments Australia
APLS

Vanguard Investments Australia’s Apellis Pharmaceuticals APLS Stock Holding History

Vanguard Investments Australia’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,240
Closed -$774K – 2378
2026
Q1 		$774K Buy
+19,240
New +$415K ﹤0.01% 1342

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Investments Australia's APLS Position: Q2 2026 in Review

Vanguard Investments Australia sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 19,240 shares — an estimated $774K sold.

Vanguard Investments Australia first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $774K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Vanguard Investments Australia reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Investments Australia sold 19,240 Apellis Pharmaceuticals shares in Q2 2026, an estimated $774K.
  • Vanguard Investments Australia first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Investments Australia's Apellis Pharmaceuticals position peaked at $774K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.